Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/150725 International Application No.: PCT/JP2017/008599
Publication Date: 08.09.2017 International Filing Date: 03.03.2017
A61K 31/519 (2006.01) ,A61K 31/337 (2006.01) ,A61K 31/436 (2006.01) ,A61K 31/4375 (2006.01) ,A61K 31/4412 (2006.01) ,A61K 31/513 (2006.01) ,A61K 31/53 (2006.01) ,A61K 31/7068 (2006.01) ,A61K 31/7072 (2006.01) ,A61K 33/24 (2006.01) ,A61K 45/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01) ,A61P 43/00 (2006.01)
[IPC code unknown for A61K 31/519][IPC code unknown for A61K 31/337][IPC code unknown for A61K 31/436][IPC code unknown for A61K 31/4375][IPC code unknown for A61K 31/4412][IPC code unknown for A61K 31/513][IPC code unknown for A61K 31/53][IPC code unknown for A61K 31/7068][IPC code unknown for A61K 31/7072][IPC code unknown for A61K 33/24][IPC code unknown for A61K 45][IPC code unknown for A61P 35][IPC code unknown for A61P 35/02][IPC code unknown for A61P 43]
大鵬薬品工業株式会社 TAIHO PHARMACEUTICAL CO., LTD. [JP/JP]; 東京都千代田区神田錦町1-27 1-27, Kandanishiki-cho, Chiyoda-ku, Tokyo 1018444, JP
三浦 晃敬 MIURA Akihiro; JP
五月女 裕 SOOTOME Hiroshi; JP
平木 祐輔 HIRAKI Yusuke; JP
藤田 節 FUJITA Takashi; JP
内藤 由美 NAITO Yumi; JP
Priority Data:
(JA) 悪性腫瘍治療用製剤及び組成物
(EN) Provided is a novel cancer treatment method using an FGFR inhibitor that exhibits a very good antitumor effect and little adverse effect. Also provided are a combination preparation for treating malignant tumors that contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof and one or a plurality of other compounds having an antitumor effect or pharmaceutically acceptable salts thereof; and a pharmaceutical composition that contains both agents. The following are also provided: an antitumor effect potentiator, an antitumor agent, a kit for treating malignant tumors, etc. that contain the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
(FR) L'invention concerne un nouveau procédé de traitement du cancer qui utilise un inhibiteur de FGFR qui présente un très bon effet anti-tumoral et peu d'effets indésirables. L'invention concerne également une préparation combinée pour le traitement de tumeurs malignes qui contient un composé représenté par la générale formule (I) ou son sel de qualité pharmaceutique et un ou plusieurs autres composés ayant un effet anti-tumoral ou leurs sels de qualité pharmaceutique ; une composition pharmaceutique qui contient les deux agents. Les éléments suivants sont également compris : un renchérisseur d'effet anti-tumoral, un agent anti-tumoral, un nécessaire de traitement de tumeurs malignes, etc. contenant le composé représenté par la formule générale (I) ou son sel de qualité pharmaceutique.
(JA) 顕著に優れた抗腫瘍効果を示し、副作用の少ないFGFR阻害剤を用いた新規な癌治療方法を提供する。 一般式(I)で表される化合物又はその薬学的に許容される塩、及び1つ又は複数の他の抗腫瘍効果を有する化合物又はその薬学的に許容される塩を含む悪性腫瘍の治療のための組合せ製剤、及び両剤を含む医薬組成物を提供する。また、一般式(I)で表される化合物又はその薬学的に許容される塩を含む抗腫瘍効果増強剤、抗腫瘍剤、悪性腫瘍治療用キット等を提供する。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)